Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 18;11:10548. doi: 10.1038/s41598-021-89981-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

miR-378c suppresses VSMCs phenotypic modulation. (A) qRT-PCR analysis of SM α-actin, calponin and miR-378c in VSMCs stimulated with PDGF-BB for 48 h after 24 h serum withdrawal. Data were presented as mean ± SD, n = 4. *P < 0.05 as compared with non-PDGF treated group. (B) qRT-PCR analysis of SM α-actin, calponin and miR-378c in serum-starved (0.1%) VSMCs. Data were presented as mean ± SD, n = 4. *P < 0.05 as compared with 0 h group. (C) qRT-PCR analysis of SM α-actin, calponin and miR-378c in VSMCs treated with PDGF-BB after 24 h serum withdrawal. Data were presented as mean ± SD, n = 4. *P < 0.05 as compared with 0 h group. (D) VSMCs stimulated with PDGF-BB for 48 h were further transfected with miR-378c mimic or mimic control, SM α-actin and calponin were analyzed by qRT–PCR. Data were presented as mean ± SD, n = 4. *P < 0.05 as compared with non-PDGF-treated group; ^#P < 0.05 as compared with PDGF-treated mimic control group. (E) VSMCs stimulated with PDGF-BB were further transfected with miR-378c inhibitor or vehicle (DMSO), VSMC differentiation markers SM α-actin and calponin were analyzed by qRT–PCR. Data were presented as mean ± SD, n = 4. *P < 0.05 as compared with non-PDGF-treated group; ^#P < 0.05 as compared with PDGF-treated vehicle group. (F) VSMCs stimulated with PDGF-BB were further transfected with miR-378c mimic or mimic control, cell numbers were examined. Data were presented as mean ± SD, n = 4. *P < 0.05 as compared with PDGF-treated mimic control group. (G) VSMCs stimulated with PDGF-BB were further transfected with miR-378c inhibitor or vehicle (DMSO), cell numbers were examined. Data were presented as mean ± SD, n = 4. *P < 0.05 as compared with PDGF-treated vehicle group.